RG-6333

RG-6333 (1,10 mg/kg, i.v. one dose) activates T cells only in the presence of T cell receptor (TCR) signaling in humanized NSG mice and does not induce a cytokine storm^[1][2].
RG-6333 (1 mg/kg, i.v. one dose) significantly inhibits tumor growth in humanized NSG mice bearing subcutaneous NALM-6 lymphoma in combination with Glofitamab (HY-P99024) (0.15 mg/kg), and increases tumor-infiltrating CD8⁺ T cells^[1].
RG-6333 (1 mg/kg, i.v. one dose) combines with Glofitamab (0.15 mg/kg) in an aggressive in vivo lymphoma (DLBCL WSU-DLCL2-Fluc) humanized mice model results in complete tumor regression, with an initial transient weight loss due to T cell activation, but subsequent recovery^[1][2].
RG-6333 (1 mg/kg, i.v. one dose) combines with glofitamab (0.15 mg/kg) in a humanized NSG mice model bearing subcutaneous OCI-Ly18 tumors increases pro-inflammatory T cell signatures in tumors and promotes transendothelial migration, and triple combination with CD19–4-1BBL deepens and prolongs anti-tumor responses in vivo^[1].